New drug may be added in the fight against mesothelioma

Mesothelioma cases study : The medical journal Cancer Chemotherapy and Pharmacology published a report from Japanese researchers test new drug, S-1, for use against mesothelioma. Although there is a rare cancer, Mesothelioma cases has no cure and it is estimated that fifteen to twenty thousand deaths per year lead over the world. Mesothelioma is asbestos toxic chemical that causes can still be used throughout the world in the construction industry. Many countries, including the United States to force all but abandoned asbestos and strict rules regarding its use and removal.Mesothelioma cases are rich with a typical wait time of twenty to fifty years continued to use asbestos completely abandoned decades rising since. The World Health Organization estimates an approaching Ninety - a thousand cases of mesothelioma per year if asbestos use pattern does not change drastically. With no known cure mesothelioma new treatments for Mesothelioma cases victims and their families are welcome.S-1 is an anti-tumor drug for gastric cancer in Japan, Korea, China and other Asian countries. Although it is not currently available for use in the U.S., S-1 has been recommended for approval in the treatment of gastric cancer in Europe. Developed by Taiho Pharmaceutical Company, known by its brand name Teysuno S-1.New mesothelioma treatments consist of surgery, chemotherapy, radiotherapy and palliative treatment options for patients to choose quality of life as a cancer-focused treatments Direct. Mesothelioma cases are often diagnosed very late in its development, life expectancy after diagnosis is short of six months to five years. Mesothelioma cases are characterized by irregularly patterned tumors in the lung lining and lining of other abdominal cavities. Pleural Mesothelioma is the cancer specifically in lung lining, while peritoneal mesothelioma cancer affect on the same feed from other abdominal cavities points. Although both are rare cancers, pleural mesothelioma is often both.S-1 was developed to prevent cancerous tumor growth, as well as support of another anti-cancer drug, 5-FU. In the study of S-1 laboratory mice received mesothelioma cells in her chest cavities that were allowed to develop for some time before the test treatments. This wait type was the typical late-stage simulate the human mesothelioma patients began treatment. It was reported that the mice well to S-1, which reduces response extended their cancer growth and survival.Researchers of the study concluded that S-1 is promising as a possible good drug for pleural mesothelioma.